WHO ICTRP trial
A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination with…
EUCTR2015-001620-33-DE · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2015-001620-33-DE |
|---|---|
| Public title | A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination with Ruxolitinib versus Placebo and Ruxolitinib in Patients with Intermediate- or High-Risk Myelofibrosis |
| Scientific title | A Phase Ib/III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of vismodegib in combination with ruxolitinib versus placebo and ruxolitinib in patients with intermediate- or high-risk myelofibrosis |
| Primary sponsor | F. Hoffmann-La Roche Ltd. |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): yes Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): no |
| Countries | France;United States;Canada;Germany;Italy |
| Conditions | Intermediate- or high-risk myelofibrosis MedDRA version: 19.1 Level: PT Classification code 10028537 Term: Myelofibrosis System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area… |
| Interventions | Trade Name: Erivedge Pharmaceutical Form: Capsule, hard INN or Proposed INN: vismodegib CAS Number: 879085-55-9 Other descriptive name: VISMODEGIB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150… |
| Registration date | Sep 16, 2015 |
| Target size | 104 |
| Secondary IDs | WO29806 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: